Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22547851 | 0.92 | SSTR4 (0.35) | SSTR4CNR2KCNH2CNR1 | |
| SCHEMBL20997665 | 0.91 | SSTR4 (0.35) | SSTR4CNR2KCNH2CNR1 | |
| SCHEMBL19687626 | 0.84 | CNR2 (0.42) | SSTR4CNR2KCNH2CNR1 | |
| SCHEMBL29324390 | 0.77 | CNR2 (0.31) | CNR2 | |
| SCHEMBL21719467 | 0.77 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL21207640 | 0.77 | SSTR4 (0.38) | SSTR4CNR2CNR1 | |
| SCHEMBL22375286 | 0.75 | KCNH2 (0.39) | CNR2KCNH2CNR1 | |
| SCHEMBL21719336 | 0.75 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL24198884 | 0.75 | NR5A1 (0.34) | CNR2 | |
| SCHEMBL24453370 | 0.74 | CNR2 (0.33) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220036-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220036-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | SSTR4 4060/4885CNR2 4319/4885KCNH2 2047/4885 |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | SSTR4 4060/4885CNR2 4319/4885KCNH2 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.